AR058598A1 - Administracion transdermica de meptazinol - Google Patents

Administracion transdermica de meptazinol

Info

Publication number
AR058598A1
AR058598A1 ARP060105700A ARP060105700A AR058598A1 AR 058598 A1 AR058598 A1 AR 058598A1 AR P060105700 A ARP060105700 A AR P060105700A AR P060105700 A ARP060105700 A AR P060105700A AR 058598 A1 AR058598 A1 AR 058598A1
Authority
AR
Argentina
Prior art keywords
meptazinol
transdermal administration
administration
increases
disclosed
Prior art date
Application number
ARP060105700A
Other languages
English (en)
Inventor
Richard Franklin
Original Assignee
Shire Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Pharmaceuticals Inc filed Critical Shire Pharmaceuticals Inc
Publication of AR058598A1 publication Critical patent/AR058598A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se divulga un sistema de administracion para la administracion de una sal de meptazinol o precursor de meptazinol que aumenta la biodisponibilidad del meptazinol a través de una cantidad eficaz para brindar un alivio analgésico. Una realizacion del sistema de administracion es un dispositivo transdérmico que aumenta el flujo del meptazinol en la piel a través de una cantidad eficaz para brindar un alivio analgésico. También se divulgan los métodos para brindar un alivio analgésico.
ARP060105700A 2005-12-21 2006-12-21 Administracion transdermica de meptazinol AR058598A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75335705P 2005-12-21 2005-12-21
US86211406P 2006-10-19 2006-10-19

Publications (1)

Publication Number Publication Date
AR058598A1 true AR058598A1 (es) 2008-02-13

Family

ID=38198475

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060105700A AR058598A1 (es) 2005-12-21 2006-12-21 Administracion transdermica de meptazinol

Country Status (15)

Country Link
US (1) US20070224253A1 (es)
EP (1) EP1962817B1 (es)
AR (1) AR058598A1 (es)
AT (1) ATE488229T1 (es)
AU (1) AU2006331596A1 (es)
CA (1) CA2633369A1 (es)
DE (1) DE602006018355D1 (es)
DK (1) DK1962817T3 (es)
EA (1) EA200801575A1 (es)
MX (1) MX2008008050A (es)
PE (1) PE20071163A1 (es)
PT (1) PT1962817E (es)
TW (1) TW200800223A (es)
UY (1) UY30056A1 (es)
WO (1) WO2007075883A2 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090280064A1 (en) * 2005-06-24 2009-11-12 Rao Papineni Transdermal delivery of optical, spect, multimodal, drug or biological cargo laden nanoparticle(s) in small animals or humans
CA2657435A1 (en) 2006-07-10 2008-07-03 Medipacs, Inc. Super elastic epoxy hydrogel
JP2011505520A (ja) 2007-12-03 2011-02-24 メディパックス インコーポレイテッド 流体計量供給装置
WO2009092071A2 (en) * 2008-01-18 2009-07-23 Shire Llc Amino acid and peptide pro-drugs of phenolic analgesics and uses thereof
CN102159205A (zh) * 2008-06-25 2011-08-17 Fe3医学有限公司 用于经皮递送治疗有效量的铁的贴片和方法
US8348922B2 (en) * 2009-02-12 2013-01-08 Incube Labs, Llc Method and apparatus for oscillatory iontophoretic transdermal delivery of a therapeutic agent
US9008765B2 (en) 2009-02-12 2015-04-14 Incube Labs, Llc System and method for biphasic transdermal iontophoretic delivery of therapeutic agents for the control of addictive cravings
US8961492B2 (en) 2009-02-12 2015-02-24 Incube Labs, Llc System and method for controlling the iontophoretic delivery of therapeutic agents based on user inhalation
US8190252B2 (en) * 2009-02-12 2012-05-29 Incube Labs, Llc Iontophoretic system for transdermal delivery of active agents for therapeutic and medicinal purposes
US8821945B2 (en) 2009-04-25 2014-09-02 Fe3 Medical, Inc. Method for transdermal iontophoretic delivery of chelated agents
US8423131B2 (en) * 2009-06-26 2013-04-16 Incube Labs, Llc Corrosion resistant electrodes for iontophoretic transdermal delivery devices and methods of use
US8903485B2 (en) 2009-08-06 2014-12-02 Incube Labs, Llc Patch and patch assembly for iontophoretic transdermal delivery of active agents for therapeutic and medicinal purposes
US9238102B2 (en) 2009-09-10 2016-01-19 Medipacs, Inc. Low profile actuator and improved method of caregiver controlled administration of therapeutics
US8685038B2 (en) 2009-12-07 2014-04-01 Incube Labs, Llc Iontophoretic apparatus and method for marking of the skin
US9500186B2 (en) 2010-02-01 2016-11-22 Medipacs, Inc. High surface area polymer actuator with gas mitigating components
AU2011213557B2 (en) 2010-02-05 2015-05-07 Phosphagenics Limited Carrier comprising non-neutralised tocopheryl phosphate
US8986279B2 (en) 2010-02-10 2015-03-24 Incube Labs, Llc Methods and architecture for power optimization of iontophoretic transdermal drug delivery
BR112012024835A2 (pt) 2010-03-30 2016-06-07 Phosphagenics Ltd adesivo de distribuição transdérmica
WO2012061556A1 (en) 2010-11-03 2012-05-10 Flugen, Inc. Wearable drug delivery device having spring drive and sliding actuation mechanism
WO2012122586A1 (en) 2011-03-15 2012-09-20 Phosphagenics Limited New composition
EP3626304A1 (en) 2011-03-24 2020-03-25 Incube Labs, Llc System and method for biphasic transdermal iontophoretic delivery of therapeutic agents
US8636696B2 (en) 2011-06-10 2014-01-28 Kimberly-Clark Worldwide, Inc. Transdermal device containing microneedles
CN104302689A (zh) 2012-03-14 2015-01-21 麦德医像公司 含有过量活性分子的智能聚合物材料
EP2961469A4 (en) 2013-02-28 2016-10-26 Kimberly Clark Co DEVICE FOR DELIVERY OF MEDICAMENT
KR102370538B1 (ko) 2013-02-28 2022-03-07 소렌토 쎄라퓨틱스, 인코포레이티드 경피 약물 전달 장치
US10376308B2 (en) 2015-02-05 2019-08-13 Axon Therapies, Inc. Devices and methods for treatment of heart failure by splanchnic nerve ablation
EP3383371B1 (en) 2015-12-09 2024-05-01 Avecho Biotechnology Limited Pharmaceutical formulation
JP7217230B2 (ja) 2016-07-29 2023-02-02 アクソン セラピーズ,インク. 内臓神経アブレーションによる心不全の治療の為のデバイス、システム及び方法
CA3045702A1 (en) 2016-12-21 2018-06-28 Phosphagenics Limited Phosphorylation process of complex alcohols
WO2019118976A1 (en) 2017-12-17 2019-06-20 Axon Therapies, Inc. Methods and devices for endovascular ablation of a splanchnic nerve
JP7334167B2 (ja) 2018-01-26 2023-08-28 アクソン セラピーズ,インク. 内臓神経の血管内アブレーションの為の方法及びデバイス
WO2020257763A1 (en) 2019-06-20 2020-12-24 Axon Therapies, Inc. Methods and devices for endovascular ablation of a splanchnic nerve
AU2021208701A1 (en) 2020-01-17 2022-07-07 Axon Therapies, Inc. Methods and devices for endovascular ablation of a splanchnic nerve
CN113491675B (zh) * 2021-07-01 2023-05-23 北京航空航天大学 一种预防瘢痕的微针创口贴及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1539277A (en) * 1977-09-16 1979-01-31 Wyeth John & Brother Ltd Hexahydro-1h-azepines
IE55189B1 (en) * 1982-07-08 1990-06-20 Wyeth John & Brother Ltd Pharmaceutical compositions
IE60941B1 (en) * 1986-07-10 1994-09-07 Elan Transdermal Ltd Transdermal drug delivery device
US6916486B2 (en) * 1996-02-19 2005-07-12 Acrux Dds Pty Ltd Transdermal delivery of analgesics
EP1094781B1 (en) * 1998-07-07 2008-07-02 Transdermal Technologies Inc. Compositions for rapid and non-irritating transdermal delivery of pharmaceutically active agents and methods for formulating such compositions and delivery thereof
US6716449B2 (en) * 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
DE10059415A1 (de) * 2000-11-30 2002-06-06 Gruenenthal Gmbh Verwendung von schwachen Opioiden und gemischten Opioidagonisten/-antagonisten zur Therapie der Harninkontinenz
JP4642467B2 (ja) * 2002-08-20 2011-03-02 ユーロ−セルティーク エス.エイ. 活性剤及び塩並びに副作用物質の遊離塩基形を含む経皮剤形
MY141815A (en) * 2003-04-30 2010-06-30 Purdue Pharma Lp Tamper-resistant transdermal dosage form comprising an active agent component and an adverse agent component at the distal site of the active agent layer

Also Published As

Publication number Publication date
PE20071163A1 (es) 2007-11-30
MX2008008050A (es) 2009-04-06
DE602006018355D1 (de) 2010-12-30
EA200801575A1 (ru) 2008-12-30
WO2007075883A2 (en) 2007-07-05
PT1962817E (pt) 2010-12-13
AU2006331596A1 (en) 2007-07-05
CA2633369A1 (en) 2007-07-05
TW200800223A (en) 2008-01-01
WO2007075883A3 (en) 2008-01-17
UY30056A1 (es) 2007-06-29
DK1962817T3 (da) 2011-03-07
ATE488229T1 (de) 2010-12-15
EP1962817A2 (en) 2008-09-03
US20070224253A1 (en) 2007-09-27
WO2007075883A9 (en) 2007-08-23
EP1962817B1 (en) 2010-11-17

Similar Documents

Publication Publication Date Title
AR058598A1 (es) Administracion transdermica de meptazinol
CR20140321A (es) Sistema de administracion transdermica que contiene buprenofina
SV2015005115A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
BR112015020466A8 (pt) inibidores de cdc7, seus usos, e composição farmacêutica
CL2015001891A1 (es) Formas de dosis de liberación controlada encerradas resistentes a manipulaciones indebidas; uso para tratar el dolor; y metodo de preparacion. (divisional de la solicitud n°2754-2014).
DOP2012000238A (es) Compuestos de para la inhibición de inmunoproteasomas
PE20191796A1 (es) Composicion farmaceutica de clorhidrato de s-ketamina
GT200900023BA (es) Formas de dosificación farmacéutica
CO6430456A2 (es) Derivados de aminotetralina, composiciones farmaceuticas que los contienen y sus usos en terapia
GT201200247A (es) Formulaciones orales y sales lipofílicas de metilnaltrexona
CR20150360A (es) Sistema de liberación transdérmica
CL2015002847A1 (es) Sistemas y métodos para tratar una respuesta farmacodinámica adversa inducida por opioides (divisional de la solicitud n° 0110-2015).
BR112013012117A8 (pt) Sistema de distribuição de fármaco iontoforético coempacotado de utilização única coempacotado autocontido, usos de fármaco e de composto de triptano
AR097619A1 (es) Uso de inhibidores de acetil-coa carboxilasa para tratar acné vulgaris
CL2008003006A1 (es) Uso de ester metilico del acido (-)-(3ar,4s,7ar)-4-hidroxi-4-m-toliletinil-octahidro-indol-1-carboxilico en base libre o en forma de sal para el tratamiento, prevencion o retraso de la progresion de la disquinesia de parkinson asociada a l-dopa; uso de la composicion farmaceutica; uso de una composicion que ademas comprende l-dopa.
CL2007002712A1 (es) Metodo para el tratamiento de un mamifero que sufre de osteoartritis que comprende administrar un agonista de lxr que modula la expresion del gen sensible lxr; y uso de un agonista lxr para el tratamiento o prevencion de la osteoartritis.
BR112012014107B8 (pt) sistema terapêutico transdérmico (tts) e processo de produção de tts
ATE524167T1 (de) Transdermales pflaster
BR112015032256A2 (pt) dispositivo com sistema terapêutico transdérmico e auxiliar de posicionamento e penetração
CL2008002465A1 (es) Composición farmacéutica anhidra tópica, que comprende derivados de niacina y un portador aceptable, su aplicacón permite un bienestar sexual mejorado.
DOP2007000055A (es) Composición farmaceutica que comprende un analgésico y vitaminas
UA108200C2 (uk) Лікарські форми та способи застосування ектопаразитоцидів
BRPI0806856A2 (pt) sistemas terapêuticos transdérmicos para administração de substâncias ativas solúveis na água
EA201301021A1 (ru) Применение пригодной для распыления композиции, содержащей амброксол
CY1120970T1 (el) Φαρμακευτικη μορφη δοσολογιας που περιλαμβανει 6'-φθορο-(ν-μεθυλ-ή ν,ν-διμεθυλ-)-4-φαινυλ-4',9'-διυδρο-3ή-σπeipo[kykλoeξano-1,1'-πυρano[3,4,b]inδoλ]-4-aminh για την αγωγη του αλγαισθητικου πονου

Legal Events

Date Code Title Description
FB Suspension of granting procedure